Tranexamic Acid Tablet, Film Coated
Product Images NDC 63629-8599

3 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Tranexamic Acid (NDC 63629-8599). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl636298599)

Label (Lbl636298599)
Label for Tranexamic Acid 650 mg tablet, film coated, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Lysteda 650 mg tablet by Teva Pharmaceuticals USA, Inc. It includes storage instructions to keep at 20°-25°C (68°-77°F) and warnings to keep out of reach of children. The label displays the NDC number 63629-8599-91 and a barcode.*
FDA Label Image

Structural Formula For Tranexamic Acid (Tranexamic Acid Tablets A202093 1)

Structural Formula For Tranexamic Acid (Tranexamic Acid Tablets A202093 1)
Chemical structure of Tranexamic Acid showing a cyclohexane ring with amino and carboxylic acid functional groups attached, depicted with stereochemical bonds indicating 3D configuration.*
FDA Label Image

Figure 1 (The efficacy of Tranexamic acid tablets 3900 mg/day over 3 menstrual cycles and over 6 menstrual cycles was demonstrated versus placebo in the double-blind, placebo-controlled efficacy studies.)

Figure 1 (The efficacy of Tranexamic acid tablets 3900 mg/day over 3 menstrual cycles and over 6 menstrual cycles was demonstrated versus placebo in the double-blind, placebo-controlled efficacy studies.)
A line graph depicting mean menstrual blood loss (mL) over a treatment period with different cycles. It compares Tranexamic Acid Tablets 3900 mg/day in a 3-cycle and 6-cycle study against placebo groups in the same study durations, showing blood loss trends from baseline through up to six treatment cycles.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.